Opens in a new tab or window The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years and older, as well as for 60- to 74-year ...
Opens in a new tab or window During last year's respiratory virus season, newly approved vaccines for respiratory syncytial virus (RSV) were effective in preventing associated hospitalizations and ...
Health Canada approves Moderna’s RSV vaccine, mRESVIA for adults aged 60 years and older: Cambridge, Massachusetts Monday, November 11, 2024, 12:00 Hrs [IST] Moderna, Inc., a le ...
AstraZeneca India and Indian Academy of Paediatrics Unite to raise awareness on respiratory syncytial virus in India: Our Bureau, Bengaluru Thursday, November 14, 2024, 16:45 Hrs ...
The patents in contention are numbers 3,109,258, 2,222,710 and 3,178,490, all awarded by the European Patent Office and covering recombinant RSV antigens and compositions and methods for making them.